Mounjaro was not originally developed as a weight loss medication. Tirzepatide was first approved as a treatment for type 2 diabetes; weight management came second. This means the evidence base in diabetes is exceptionally strong. The answer is yes. Mounjaro is both licensed and clinically well-supported for type 2 diabetes. But there are important nuances around how it works in this population, which medications it interacts with, and what requires closer monitoring.
Why Mounjaro is particularly valuable in type 2 diabetes
In non-diabetic patients, tirzepatide primarily suppresses appetite and drives weight loss. In type 2 diabetes, it additionally addresses the core pathophysiology directly:
- Stimulates insulin secretion in a glucose-dependent manner: only increases insulin when blood glucose is elevated, reducing hypoglycaemia risk compared to sulphonylureas
- Suppresses glucagon: reducing the liver's inappropriate glucose output between meals
- Reduces post-meal blood glucose spikes by slowing gastric emptying
- Improves insulin sensitivity in peripheral tissues, addressing the core defect of type 2 diabetes
- Produces significant weight loss: which independently improves insulin sensitivity and glycaemic control
In SURPASS-2 (Frías JP et al, N Engl J Med 2021, n=1,879), tirzepatide at all three doses was superior to semaglutide 1mg for both HbA1c reduction and weight loss. Tirzepatide 15mg reduced HbA1c by an average of 2.3 percentage points: exceeding the reduction seen with most existing diabetes medications.
How does weight loss compare in diabetic vs non-diabetic patients?
Important distinction. In the SURMOUNT-1 trial (New England Journal of Medicine, 2022), adults without diabetes who took tirzepatide 15mg alongside diet and activity advice lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo, counting everyone who started treatment. Among people who stayed on treatment, the average was 22.5%. On 15mg, 91% lost at least 5% of their weight, compared with 35% on placebo. Individual results vary.
In the SURMOUNT-2 trial (The Lancet, 2023), 938 adults with type 2 diabetes and a BMI of 27 or more lost an average of 12.8% of their body weight on tirzepatide 10mg and 14.7% on 15mg over 72 weeks, compared with 3.2% on placebo, counting everyone who started treatment. Among people who stayed on treatment, the averages were 13.4% and 15.7%: still substantial and clinically meaningful, but lower than the non-diabetic population. Individual results vary. Patients with type 2 diabetes should be aware their expected results may be towards the lower end of the clinical trial range.
Interactions with other diabetes medications
Insulin: Combined with tirzepatide, the risk of hypoglycaemia is real. Insulin doses typically need to be reduced when tirzepatide is started, only under clinical supervision. Never reduce insulin independently. Your prescribing pharmacist or diabetes team will monitor and adjust.
Sulphonylureas (gliclazide, glipizide, glibenclamide): Cause insulin release regardless of blood glucose level. Combined with tirzepatide, hypoglycaemia risk increases. Dose reduction of the sulphonylurea is often required when tirzepatide is initiated.
Metformin: No significant interaction. Frequently used together with tirzepatide with good complementary effect. No dose adjustment typically required.
SGLT-2 inhibitors (dapagliflozin, empagliflozin): No significant interaction. Compatible with tirzepatide. Some patients benefit from continuing SGLT-2 inhibitors alongside Mounjaro, particularly those with cardiovascular or renal comorbidities.
DPP-4 inhibitors (sitagliptin, saxagliptin): Significantly overlap with tirzepatide's mechanism (both act on the GLP-1 pathway). Combining both is not recommended. The DPP-4 inhibitor is typically discontinued when tirzepatide is started.
Blood glucose monitoring
Patients with type 2 diabetes starting Mounjaro should monitor blood glucose more frequently during the initial weeks and after each dose increase. Particularly important for patients on insulin or sulphonylureas, proactive monitoring allows dose adjustment before hypoglycaemia occurs. Regular monitoring also guides HbA1c assessment and dose decisions.
HbA1c improvements
Beyond weight loss, tirzepatide produces significant HbA1c reductions, among the strongest of any available diabetes medication. For many patients, initiating Mounjaro may allow simplification of their diabetes treatment regimen, potentially reducing or eliminating the need for other medications, under medical supervision.
Is Mounjaro suitable for all patients with type 2 diabetes?
Your pharmacist checks for anything that rules treatment out or needs extra care: an allergy to tirzepatide, a personal or family history of medullary thyroid cancer or MEN2, previous pancreatitis, and pregnancy or breastfeeding. Type 1 diabetes: not indicated and carries risks. Severe gastroparesis: tirzepatide has not been studied in severe gastrointestinal disease, including severe gastroparesis, and the UK product information advises caution, because it slows stomach emptying. History of significant GI surgery: requires careful individual assessment.
NHS Mounjaro for diabetic patients
Tirzepatide is available on the NHS through specialist diabetes services for patients with type 2 diabetes, a separate pathway from the obesity management rollout. If you have type 2 diabetes and are not yet accessing NHS Mounjaro, speak to your diabetes specialist or GP about whether you qualify under the diabetes indication.